Myocardial infarction and its evolution towards heart failure is a leading cause of death in Europe. No curative treatment aside heart transplantation has been accomplished so far. DNABEATS aims to bring advanced materials to regenerate injured myocardium. Cutting-edge DNA nanotechnology is exploited for the fabrication of fully customised biocompatible DNA-based nanocarriers (DNCs) to achieve the cardio-targeted and efficient delivery of a regenerative microRNA. The therapeutic efficacy of DNCs will be assessed in human-derived cardiac cells, a ground-breaking aspect, that together with an exhaustive in vitro and in vivo biocompatibility investigation, will facilitate their future clinical application and industrial transfer.